New combo therapy shows promise for tough esophageal cancer
NCT ID NCT02642809
First seen Mar 23, 2026 · Last updated May 07, 2026 · Updated 6 times
Summary
This early-phase study tested a new approach for people with metastatic esophageal cancer (cancer that has spread). It combined a short, strong dose of internal radiation (brachytherapy) with the immunotherapy drug pembrolizumab. The goal was to see if the radiation could help the immune system fight the cancer better. The study involved 16 participants and focused mainly on safety and tumor changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.